Loading data for CLDX — first visit, this takes a few seconds.

Preisalarm

Celldex Therapeutics Inc. (CLDX)

NasdaqCM: CLDX · Echtzeitkurs · USD

42.23

+0.44 (1.05%)

Zum Schluss: Aug 18, 2026, 3:59 PM

1.05% (1D)

Geld	36.43
Marktkapitalisierung	3.28 Mrd
Umsatz (TTM)	158K
Nettogewinn (TTM)	-300.55 Mio
Beta	0.84
EPS (ttm)	-4.35
KGV (TTM)	n/a
Forward-KGV	-10.04
KBV (TTM)	4.59
KUV (TTM)	20770.57
Earnings Date	Nov 9, 2026

Brief	48.47
Volumen	249,041
Ø Vol. (20D)	1,032,000
Eröffnung	42.51
Vortagesschluss	41.79
Tagesspanne	41.73 - 43.20
52-Wk Range	20.37 - 45.14
Analyst	n/a
Kursziel	n/a
Dividenden	n/a
Ex-Dividenden-Datum	n/a

Über CLDX

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that spe...

[Mehr lesen]

Branche Biotechnology

Sektor Healthcare

IPO Datum May 15, 1986

Mitarbeiter 198

Börse NasdaqCM

Tickersymbol CLDX

Website https://www.celldex.com

Vollständiges Unternehmensprofil

Finanzielle Entwicklung

Im Jahr 2025 betrug der Umsatz von Celldex Therapeutics 1.54 Mio, ein Rückgang von -77.99% im Vergleich zum Vorjahr (7.02 Mio). Der Gewinn lag bei -258.76 Mio, ein Anstieg von 63.91 %.

Finanzberichte

Gewinnüberraschung

Celldex Therapeutics hat die Quartalszahlen am Aug 6, 2026 veröffentlicht:

Umsatz von $22K verfehlt die Erwartungen um $0, mit -96.99% Rückgang im Jahresvergleich.

EPS von -0.94 übertrifft die Erwartungen um 0.12, mit -10.59% Rückgang im Jahresvergleich.

Nächste Ergebnisveröffentlichung

Celldex Therapeutics Inc. wird voraussichtlich die Quartalszahlen veröffentlichen am Nov 9, 2026, während der Handelszeiten.
Analysten erwarten einen Umsatz von ... Upgrade

Nachrichten

vor 1 Woche · Simply Wall St.

Celldex Therapeutics (CLDX) Could Be 130% Undervalued After Second Quarter Results

Celldex Therapeutics (CLDX) released its second quarter 2026 results on 6 August, reporting very limited revenue and a wider net loss. This places the stock’s recent strength in sharper focus for inve...

vor 1 Woche · Simply Wall St.

Is Celldex Therapeutics’ (CLDX) Growing Losses With Minimal Revenue a Strategic Bet or Structural Concern?

Celldex Therapeutics, Inc. recently reported second-quarter 2026 results, with revenue falling to US$0.022 million and net loss widening to US$73.5 million, while loss per share from continuing operat...

vor 1 Woche · Simply Wall St.

Celldex Therapeutics (CLDX) Stock Trades At A Premium Despite A 102% Return

Celldex Therapeutics stock has more than doubled over the past year, yet its broader valuation checks lean expensive rather than cheap, which raises questions about how much of its pipeline story is a...

vor 1 Woche · Simply Wall St.

What Is Celldex Therapeutics (CLDX) Signaling With Its Mixed Pipeline Update?

Celldex Therapeutics (NasdaqCM:CLDX) reported updated clinical pipeline data, including positive Phase 1 results for bispecific antibody CDX-622. The company outlined progress on ongoing Phase 3 studi...

vor 1 Woche · Zacks

Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates

Celldex (CLDX) delivered earnings and revenue surprises of +9.62% and -98.75%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Seite 1 von 2

Celldex Therapeutics Inc. (CLDX)